Bicara Therapeutics Inc. Common Stock
BCAX | NASDAQ
$22.01
-$0.63 (-2.78%)
At close: Sep 21, 2026, 4:00 PM ET
$22.01
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -59.95M | -60.24M | -41.12M | -40.68M | -32.02M | -41.79M | -26.64M | -20.63M | -19.75M | -15.37M | -13.69M | -9.53M | -8.34M | -8.34M |
Interest Income | 4.58M | 4.08M | 3.79M | 4.39M | 4.68M | 5.01M | 5.87M | 3.15M | 2.7M | 2.87M | 1.3M | 13K | n/a | n/a |
Pretax Income | -55.38M | -56.16M | -37.33M | -36.29M | -27.34M | -36.77M | -20.77M | -17.48M | -17.05M | -12.51M | -12.44M | -22.85M | -8.35M | -8.35M |
Net Income | -55.44M | -56.21M | -37.39M | -36.33M | -27.39M | -36.85M | -20.96M | -17.48M | -17.05M | -12.51M | -12.44M | -22.85M | -8.35M | -8.35M |
Selling & General & Admin | 14.18M | 12.74M | 8.13M | 7.7M | 7.22M | 7.46M | 6.75M | 4.76M | 3.91M | 3.34M | 3.13M | 2.59M | 1.78M | 1.78M |
Research & Development | 45.77M | 47.5M | 32.99M | 5.82M | 24.8M | 34.33M | 19.88M | 15.86M | 15.84M | 12.03M | 10.56M | 6.94M | 6.56M | 6.56M |
Other Expenses | n/a | n/a | n/a | 27.16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 59.95M | 60.24M | 41.12M | 40.68M | 32.02M | 41.79M | 26.64M | 20.63M | 19.75M | 15.37M | 13.69M | 9.53M | 8.34M | 8.34M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 59.95M | 60.24M | 41.12M | 40.68M | 32.02M | 41.79M | 26.64M | 20.63M | 19.75M | 15.37M | 13.69M | 9.53M | 8.34M | 8.34M |
Income Tax Expense | 61K | -52K | 53K | 40K | 52K | 72K | 186K | n/a | n/a | 1K | 5K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 67.93M | 60.72M | 55.14M | 54.56M | 54.54M | 54.46M | 54.44M | 54.41M | 54.18M | 54.18M | 53.09M | 54.41M | 54.6M | 54.6M |
Shares Outstanding (Diluted) | 67.93M | 60.72M | 55.14M | 54.56M | 54.54M | 54.46M | 54.44M | 54.41M | 54.18M | 54.18M | 53.09M | 54.41M | 54.62M | 54.62M |
EPS (Basic) | -0.82 | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 | -0.38 | -0.32 | -0.27 | -0.27 | -0.23 | -0.42 | -0.15 | -0.15 |
EPS (Diluted) | -0.82 | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 | -0.38 | -0.32 | -0.27 | -0.27 | -0.23 | -0.42 | -0.15 | -0.15 |
EBITDA | -54.71M | -56.12M | -37.32M | -36.23M | -27.32M | -36.76M | -20.76M | -17.47M | -17.04M | -12.49M | -25.76M | -22.84M | -8.35M | -8.35M |
EBIT | -55.38M | -56.16M | -37.33M | -36.29M | -27.34M | -36.77M | -20.77M | -17.48M | -17.05M | -12.51M | -25.78M | -22.85M | -8.35M | -8.35M |
Depreciation & Amortization | 663K | 44K | 11K | 56K | 19K | 19K | 15K | 15K | 13K | 13K | 14K | 2K | 1.5K | 1.5K |
Add to Watchlist
Select watchlists to add or remove BCAX